Atrys Health Stock

Atrys Health P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Atrys Health (ATRY.MC) as of Aug 6, 2026 is -137.43. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 71.49 — a change of -292.24% (lower).

P/CF

-137.43

YoY

-292.24%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Atrys Health is 2026 -137.43 . P/CF (Price-to-Cash-Flow Ratio) of Atrys Health was 2025 71.49 . It decreases by -292.24% lower compared to the previous year.
Access this data via the Eulerpool API

Atrys Health Stock analysis

What does Atrys Health do? Atrys Health SA is a leading provider of medical services, founded in 2007 in Madrid, Spain, as a spin-off company of the Clinica Universidad de Navarra. The company's goal is to connect the limitless world of science and technology with the human component of healthcare. The business model of Atrys Health specializes in the development of products, services, and solutions in the field of medical imaging and cancer treatment. The company offers innovative technologies and medical services to help diagnose and treat patients better. Atrys Health consists of different business divisions focusing on the needs of clinical practice, research and development, and biotechnological production. The company aims to improve the efficiency and effectiveness of diagnosis, imaging, and treatment technologies to maximize results. The divisions of Atrys Health focus on various aspects of healthcare, including telemedicine, radiology, and proton therapy. Telemedicine provides a platform for remote treatments and medical consultation, improving access to specialists and enabling fast and effective diagnosis and treatment. The radiology division operates diagnostic centers specializing in medical imaging, equipped with the latest imaging technologies. The proton therapy division operates a proton therapy center in Madrid, offering advanced cancer treatment. Atrys Health offers a range of products tailored to the needs of clinical practice, research and development, and biotechnological production. Their key products include Atrilab, a leading platform for precision oncology diagnostics, Auriculum, a technology for precise radiation in cancer treatments, and Vida Oncology, a software solution for cancer treatment management. In conclusion, Atrys Health is a key player in medical imaging and cancer treatment, improving healthcare globally with advanced technologies and services. With their vision of combining innovative technologies with the human component of healthcare, Atrys Health will continue to lead in the healthcare industry. Atrys Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Atrys Health stock

P/CF (Price-to-Cash-Flow Ratio) of Atrys Health is -137.43 in 2026.

P/CF (Price-to-Cash-Flow Ratio) of Atrys Health changed from 71.49 to -137.43, representing a -292.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Atrys Health since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Atrys Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Atrys Health

All Key Metrics — Atrys Health